| MERCK KGAA O.N. | 134.10 / -0.52% |
| Date/Time | 10/28 / 17:29 |
| Chg. / Chg.(%) | -0.70 / -0.52% |
| Bid | 133.95 / 150 |
| Ask | 134.65 / 150 |
| Open | 132.75 |
| Previous Close | 134.80 |
| High | 136.25 |
| Low | 132.75 |
| Volume [EUR] | 17,482.50 |
| Volume [Units] | 130 |
| Price fixings | 5 |
| ISIN | DE0006599905 |
| Security | MRK |
| Exchange | Düsseldorf |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 134.75 |  |
903,504 |
| Cboe Europe .. | 134.00 | |
197,488 |
| Turquoise | 133.95 | |
170,952 |
| Cboe Europe .. | 133.95 | |
130,276 |
| London Inter.. | 134.75 | |
74,135 |
| TradeGate | 134.650 | |
15,953 |
| Stuttgart | 134.000 | |
4,316 |
| Frankfurt | 134.4000 | |
1,997 |
| gettex | 134.050 | |
693 |
| Borsa Italia.. | 134.65 |  |
494 |
| Düsseldorf | 134.10 | |
130 |
| München | 134.30 | |
94 |
| Hannover | 135.35 | |
45 |
| Hamburg | 134.60 | |
44 |
| Nasdaq Other.. | 156.8000 | |
6 |
| Vienna Globa.. | 134.10 | |
0 |
| Berlin | 133.75 | |
0 |
| Lang & Schwa.. | 133.950 | |
|
| SIX Swiss Ex.. | 130.00 | ||
| SIX Swiss Ex.. | 109.60 | ||
| EUREX | Options | ||
News
- Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer
07:15 - GlobeNewswire - Merck revenue rises 1% YoY to $12.6B in Q3
10/27/2020 / 11:56 - TeleTrader - Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
09/17/2020 / 14:00 - GlobeNewswire - PTA-News: 4SC AG: 4SC expands avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer<BR/>for further clinical combination study of domatinostat in Merkel cell carcinoma
09/15/2020 / 07:30 - pressetext - NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
09/09/2020 / 01:00 - GlobeNewswire
Real-time